These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6487703)

  • 1. Assessment of biomaterials as components of a reciprocating dialyser during canine dialysis.
    Davidson GW; Peppas NA; Thornhill JA; Ash SR
    Biomaterials; 1984 Jul; 5(4):227-33. PubMed ID: 6487703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of vitamin-E-modified dialysers on dialyser clotting, erythropoietin and heparin dosage: a comparative crossover study.
    Huraib S; Tanimu D; Shaheen F; Hejaili F; Giles C; Pagayon V
    Am J Nephrol; 2000; 20(5):364-8. PubMed ID: 11092992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the sorbent suspension reciprocating dialyser in the treatment of overdose of paracetamol and phenobarbitone.
    Shihab-Eldeen AA; Peck GE; Ash SR; Kaufman G
    J Pharm Pharmacol; 1988 Jun; 40(6):381-7. PubMed ID: 2901467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma recalcification as a measure of contact phase activation and heparinization efficacy after contact with biomaterials.
    Rhodes NP; Williams DF
    Biomaterials; 1994 Jan; 15(1):35-7. PubMed ID: 8161655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
    Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
    Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-free hemodialysis with prophylactic change of dialyser and blood lines.
    Preuschof L; Keller F; Seemann J; Offermann G
    Int J Artif Organs; 1988 Jul; 11(4):255-8. PubMed ID: 3410566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors of system clotting in heparin-free haemodialysis.
    Keller F; Seemann J; Preuschof L; Offermann G
    Nephrol Dial Transplant; 1990; 5(9):802-7. PubMed ID: 2129354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin free dialysis: comparative data and results in high risk patients.
    Caruana RJ; Raja RM; Bush JV; Kramer MS; Goldstein SJ
    Kidney Int; 1987 Jun; 31(6):1351-5. PubMed ID: 3613407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimodule dialyser for quantitative ex vivo evaluation of membrane haemocompatibility in humans: comparison of acrylonitrile copolymer, cuprophan and polysulphone hollow fibres.
    Mulvihill J; Cazenave JP; Mazzucotelli JP; Crost T; Collier C; Renaux JL; Pusineri C
    Biomaterials; 1992; 13(8):527-36. PubMed ID: 1633226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemodialysis in dogs with a heparin coated hollow fibre dialyser.
    Lins LE; Olsson P; Hjelte MB; Larsson R; Larm O
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():270-5. PubMed ID: 3991510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a new parallel-flow, plate dialyser and a hollow fibre dialyser.
    Sølling J; Hansen HE
    Scand J Urol Nephrol; 1979; 13(3):305-7. PubMed ID: 394310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of haemodialysis membrane biocompatibility by parallel assessment in an ex vivo model in healthy volunteers.
    Mulvihill J; Crost T; Renaux JL; Cazenave JP
    Nephrol Dial Transplant; 1997 Sep; 12(9):1968-73. PubMed ID: 9306352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
    Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
    Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the clotting system: heparin-coated versus non coated systems for extracorporeal circulation.
    Urlesberger B; Zobel G; Rödl S; Dacar D; Friehs I; Leschnik B; Muntean W
    Int J Artif Organs; 1997 Dec; 20(12):708-12. PubMed ID: 9506788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Minimal heparinization in dialysis patients with increased risk of bleeding].
    Klingel R; Wandel E; Hafner G; Meyer zum Büschenfelde KH; Köhler H
    Dtsch Med Wochenschr; 1993 Dec; 118(51-52):1878-83. PubMed ID: 8287777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.
    Kurec AS; Morris MW; Davey FR
    Ann Clin Lab Sci; 1979; 9(6):494-500. PubMed ID: 518012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired anticoagulant effect of heparin in the artificial kidney. An experimental study.
    Björnson J; Godal HC
    Scand J Clin Lab Invest; 1976 Oct; 36(6):581-9. PubMed ID: 1006146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocyte subsets in dialyser eluates: a new parameter of bioincompatibility?
    Grooteman MP; Nube MJ; van Limbeek J; Schoorl M; van Houte AJ
    Nephrol Dial Transplant; 1996 Jun; 11(6):1073-8. PubMed ID: 8671971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated coagulation time in monitoring heparinized dogs.
    Green RA
    Am J Vet Res; 1980 Nov; 41(11):1793-7. PubMed ID: 7212408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.